96. クローン病 Crohn disease Clinical trials / Disease details
臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03773237 (ClinicalTrials.gov) | December 31, 2018 | 12/11/2018 | Intralipid Versus SMOFlipid in HPN Patients | Randomized Prospective Trial Comparing Intralipid Versus SMOFlipid in New HPN Patients. | Short Bowel Syndrome;Intestinal Fistula;Crohn Disease;Intestinal Obstruction | Dietary Supplement: SMOFLipid;Dietary Supplement: Intralipid | Mayo Clinic | NULL | Active, not recruiting | 18 Years | 75 Years | All | 22 | N/A | United States |
| 2 | NCT02349594 (ClinicalTrials.gov) | January 2014 | 16/1/2015 | Immune Modulation by Parenteral Fish Oil in Patients With Crohn's Disease | Modulation of Immune Function by Parenteral Fish Oil in Patients With Crohn's Disease and High Inherent Tumor Necrosis Factor-alpha Production: a Randomized, Single Blinded, Cross-over Study | Crohn Disease | Drug: Omegaven 10%;Drug: Intralipid 20% | Radboud University | NULL | Completed | 18 Years | 70 Years | Both | 6 | Phase 4 | Netherlands |
| 3 | EUCTR2013-001212-30-NL (EUCTR) | 04/07/2013 | 18/06/2013 | Immune modulation by parenteral Fish oil in patients with Crohn’s disease | Modulation of immune function by parenteral fish oil in patients with Crohn’s disease and high inherent Tumor Necrosis Factor-alfa production, a randomized, single blinded, cross-over study | Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: Omegaven Trade Name: Intralipid 10% | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands |